<?xml version="1.0" encoding="UTF-8"?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9">
  <url><loc>https://peptide.global/story/once-monthly-semaglutide-korea-trials</loc><news:news><news:publication><news:name>Peptide Global</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-19T13:47:00.000Z</news:publication_date><news:title>Once monthly semaglutide trials from Daewoong and Peptron win Korean approval on the same day</news:title></news:news></url>
  <url><loc>https://peptide.global/story/korea-obesity-drug-imports-oversight</loc><news:news><news:publication><news:name>Peptide Global</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-19T13:19:00.000Z</news:publication_date><news:title>Korean doctors want obesity drug imports tracked from customs to clinic and prices cut at home</news:title></news:news></url>
  <url><loc>https://peptide.global/story/mounjaro-cardiovascular-indication-health-canada</loc><news:news><news:publication><news:name>Peptide Global</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-19T12:53:00.000Z</news:publication_date><news:title>Mounjaro cardiovascular indication approved by Health Canada after a head to head trial with Trulicity</news:title></news:news></url>
  <url><loc>https://peptide.global/story/kyinsu-indication-eu-widen</loc><news:news><news:publication><news:name>Peptide Global</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-19T12:27:00.000Z</news:publication_date><news:title>Kyinsu indication in the EU set to widen as the label waits on a Commission decision</news:title></news:news></url>
  <url><loc>https://peptide.global/story/pwc-weight-loss-drugs-india-households</loc><news:news><news:publication><news:name>Peptide Global</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18T18:25:00.000Z</news:publication_date><news:title>Weight loss drugs in India reach two lakh households as PwC says use doubles each year</news:title></news:news></url>
  <url><loc>https://peptide.global/story/indian-generic-semaglutide-overseas-push</loc><news:news><news:publication><news:name>Peptide Global</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18T17:35:00.000Z</news:publication_date><news:title>Indian generic semaglutide makers push into Canada Brazil and Africa as home prices slide</news:title></news:news></url>
  <url><loc>https://peptide.global/story/dunnhumby-survey-glp-1-use-americas</loc><news:news><news:publication><news:name>Peptide Global</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18T17:04:00.000Z</news:publication_date><news:title>Dunnhumby survey finds cost holds back GLP 1 use across the Americas as Brazil nears US levels</news:title></news:news></url>
  <url><loc>https://peptide.global/story/zeydovio-approval-eu-short-bowel</loc><news:news><news:publication><news:name>Peptide Global</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18T16:30:00.000Z</news:publication_date><news:title>Zeydovio approval in the EU gives short bowel syndrome patients a twice weekly GLP 2 option</news:title></news:news></url>
  <url><loc>https://peptide.global/story/hanmi-eppe-64-week-weight-loss</loc><news:news><news:publication><news:name>Peptide Global</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18T16:11:00.000Z</news:publication_date><news:title>Hanmi Eppe 64 week data show weight loss holding above 10 percent in Korean Phase 3</news:title></news:news></url>
</urlset>